Metadata: In Vitro and In Vivo Data for Engineered Macrophage Hyperuricemia Therapy

Metadata from a figshare dataset by Yuzhong Feng, last updated April 20, 2026. The dataset contains experimental results from a study engineering RAW264.7 macrophages to co-express uricase and URAT1 for hyperuricemia therapy. It includes in vitro uric acid degradation measurements and in vivo efficacy and safety data from mouse models.

Use Cases

• Modeling uric acid degradation kinetics based on in vitro time-course data mentioned in the description
• Comparing therapeutic efficacy between engineered macrophages and Rasburicase based on serum uric acid levels in mouse models
• Assessing immunogenicity profiles based on anti-uricase antibody measurements described
• Analyzing inflammatory cytokine reduction (IL-1β, IL-6, TNF-α) as a safety outcome in hyperuricemic mice

Strengths

• Includes specific quantitative results, such as uric acid reduction from 556.0 ± 37.0 μmol/L to 0.7 ± 0.6 μmol/L
• Provides comparative data between the engineered macrophage system and the drug Rasburicase, with statistical significance (P < 0.05) noted
• Contains safety assessment data, including liver/renal function and cytokine levels

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small (25.3 KB), indicating limited scope and likely a summary of key results rather than raw experimental data

Provenance

Source

Yuzhong Feng via figshare

Collection Method

Experimental data from in vitro assays and in vivo mouse models, as described in the study summary.

Time Range

The study period is not specified, but the dataset was updated in 2026.

Freshness

Last updated 2026-04-20 17:43:19; freshness should be verified

Geography

Not specified; likely laboratory-based research.